Nomogram for Individualized Prediction of Survival after Immunotherapy for Extensive-Stage Small Cell Lung Cancer

Purpose This study aimed to develop and validate a nomogram utilizing non-invasive baseline features to predict survival in patients with extensive-stage small cell lung cancer (ES-SCLC) undergoing immunotherapy. Methods This retrospective study included patients with ES-SCLC admitted to Shandong Provincial Hospital Affiliated to Shandong First Medical University between May 2020 and May 2023. Baseline clinical, radiological, serological, and pathological data were collected, with illness status monitored at regular intervals. Survival prediction nomograms were constructed using multivariate Cox regression analysis of the training cohort and validated in an independent internal cohort. Model performance was evaluated through Receiver Operating Characteristic (ROC) curves, C-indices, calibration curves, and Decision Curve Analysis (DCA). Results A total of 183 immunotherapy-treated ES-SCLC patients were included in the analysis. They were assigned to either a training cohort (n = 128) or a validation cohort (n = 55) through randomization based on a 7:3 ratio. Multivariate Cox regression analysis identified liver metastasis, elevated neuron-specific enolase (NSE), and increased pro-gastrin-releasing peptide (Pro-GRP) as independent risk factors for poor progression-free survival (PFS) and overall survival (OS) in the training cohort (P < 0.05). A prognostic nomogram was developed based on these factors. The risk scoring system revealed a significant association between risk categories and patient survival, with low-risk cases having more favorable PFS and OS outcomes than their high-risk counterparts. Conclusion The nomogram, based on non-invasive screening, effectively predicts survival outcomes in patients with ES-SCLC receiving immunotherapy, offering a tool for pre-treatment risk stratification and informed treatment decision-making.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11117524/v1
Primary Topic
Lung Cancer Research Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Nomogram for Individualized Prediction of Survival after Immunotherapy for Extensive-Stage Small Cell Lung Cancer

Guobin Fu, Fengxian Jiang, Jingjiang Lai, Cuiyan Wang et al.
5 links
Research Square
Lung Cancer Research Studies
preprint

Nomogram for Individualized Prediction of Survival after Immunotherapy for Extensive-Stage Small Cell Lung Cancer

Guobin Fu, Fengxian Jiang, Jingjiang Lai, Cuiyan Wang, Shu Yang, Zhizhao Zhang, Pancen Ran, Jingliang Wang, Wei Xu, Xiaodi Xie, Jun Ma, Jing Zhao, Lei Liu
preprint en

Abstract

Purpose This study aimed to develop and validate a nomogram utilizing non-invasive baseline features to predict survival in patients with extensive-stage small cell lung cancer (ES-SCLC) undergoing immunotherapy. Methods This retrospective study included patients with ES-SCLC admitted to Shandong Provincial Hospital Affiliated to Shandong First Medical University between May 2020 and May 2023. Baseline clinical, radiological, serological, and pathological data were collected, with illness status monitored at regular intervals. Survival prediction nomograms were constructed using multivariate Cox regression analysis of the training cohort and validated in an independent internal cohort. Model performance was evaluated through Receiver Operating Characteristic (ROC) curves, C-indices, calibration curves, and Decision Curve Analysis (DCA). Results A total of 183 immunotherapy-treated ES-SCLC patients were included in the analysis. They were assigned to either a training cohort (n = 128) or a validation cohort (n = 55) through randomization based on a 7:3 ratio. Multivariate Cox regression analysis identified liver metastasis, elevated neuron-specific enolase (NSE), and increased pro-gastrin-releasing peptide (Pro-GRP) as independent risk factors for poor progression-free survival (PFS) and overall survival (OS) in the training cohort (P < 0.05). A prognostic nomogram was developed based on these factors. The risk scoring system revealed a significant association between risk categories and patient survival, with low-risk cases having more favorable PFS and OS outcomes than their high-risk counterparts. Conclusion The nomogram, based on non-invasive screening, effectively predicts survival outcomes in patients with ES-SCLC receiving immunotherapy, offering a tool for pre-treatment risk stratification and informed treatment decision-making.

Research Square
Shandong University of Traditional Chinese Medicine (CN), Shandong Tumor Hospital (CN), Shandong Provincial Hospital (CN), Shandong First Medical University (CN)
Good health and well-being
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon